Staffan Encrantz sold $2.1M of Sight Sciences (SGHT)

Executed Nov 21 2024, disclosed Nov 21 2024, the same day.

Value, as filed

$2.1M

551,802 sh × $3.73

Executed

Nov 21 2024

the trade date, as filed

Disclosed

Nov 21 2024

0 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

Staffan Encrantz Director profile →

Staffan Encrantz (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Sight Sciences, Inc. (SGHT). Across 1 priced purchase filing, the average 21-session return was -20.6% from execution and -25.6% from disclosure (delay-adjusted; derived). The largest single filing was $116K of SGHT (13,958 sh × $8.31, as filed), executed Dec 16 2025.

The name

SGHT

Sight Sciences, Inc. SGHT · Healthcare · 14 filings in 24 months ticker →

Healthcare · Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical te…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Staffan Encrantz in SGHT

SGHTPURCHASE Sight Sciences, Inc. $116K
13,958 sh × $8.31
Exec Dec 16 2025
Filed Dec 18 2025 · 6:10 PM ET SGHTPURCHASE Sight Sciences, Inc. $291K
68,851 sh across 2 lots
Exec Jun 5 2025
Filed Jun 6 2025 · 5:30 PM ET SGHTPURCHASE Sight Sciences, Inc. $377K
98,782 sh across 3 lots
Exec May 30 2025
Filed Jun 3 2025 · 5:30 PM ET SGHTPURCHASE Sight Sciences, Inc. $358K
101,474 sh across 2 lots
Exec May 27 2025
Filed May 29 2025 · 5:30 PM ET SGHTPURCHASE Sight Sciences, Inc. $2.1M
551,802 sh × $3.73
Exec Nov 21 2024
Filed Nov 21 2024 · 5:30 PM ET